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very receTo the Editor
In their recent contribution to Atherosclerosis, Tang et al. [1] have
hypothesized that a PCSK9 gene interference could directly sup-
press atheroma development by decreasing vascular inﬂammation,
suggesting that this might be the protective mechanism of PCSK9
inhibitors (PCSK9i) in coronary patients. The major end-point trials
do not clearly indicate that an anti-inﬂammatory activity of both
bococizumab [2] and evolocumab [3] may be responsible for the
observed coronary prevention, while in a combined analysis of
these trials, the impressive LDL-cholesterol reductions appeared
to be deﬁnitely responsible for the lower cardiovascular outcomes,
with a nearly identical effect on risk as that of statins [4]. An as yet
not underlined ﬁnding of the bococizumab (SPIRE-1 and SPIRE-2)
[2] and evolocumab trials was the absence of changes in high-
sensitivity C-reactive protein (hsCRP) levels [3]. These ﬁndings
conﬁrm the results of a careful meta-analysis from many trials
with PCSK9i, showing a lack of activity on CRP levels (evolocumab:
weighed mean difference (WMD) 0.002 mg/L; alirocumab WMD
0.15 mg/L) [5]. A similar lack of activity was reported for the RNAi
therapeutic agent inclisiran [6].
Interestingly, data from the ODYSSEY COMBO II trial [7] show
that PCSK9i may work better in CV patients with residual lipid
(LDL-C >70 mg/dL) risk, but not with residual inﬂammatory risk
(CRP > 2 mg/dL). In addition, in this trial, ezetimibe was certainly
far less effective on LDL cholesterolemia (20.7 ± 1.9% and
50.6 ± 1.4% for ezetimibe and alirocumab, respectively), but it
lowered CRP by 25% (baseline, 34.6 nmol/L; week 52, 25.7 nmol/
L) vs. no effect of alirocumab (baseline, 34.1; week 52, 33.4 nmol/
L) [7]. At both the ﬁrst [7] and two-year follow-ups, a reduction
of coronary procedures with ezetimibe was reported [8]. Obviously,
the apo-E knockout mouse in the Tang et al. [1] report provides a
distant model from the coronary patient and the acute formation
of plaques in this model certainly differs from the slow growth
found in the clinical disease.
The lack of activity of PCSK9i on CRP levels is somewhat at odds
with the supporting evidence of the importance of CRP reduction in
preventing CV risk. This view has been well supported by the suc-
cessful conclusions of e.g. the JUPITER Study [9], based on theica, et al., PCSK9 antagonistf high-CRP patients, and other similar studies, (e.g. the
nt CANTOS Study with canakizumab) [10].
Finally, the use of PCSK9 inhibitors clearly demonstrated the
lack of an association of changes in hs-CRP levels and LDL-
cholesterol reduction (p ¼ 0.697) [11]; these are usually directly
correlated under statin treatment.
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